CAMP (34) LFCR (51) ELDN (49) EVMN (43) ⌘ Pro Terminal →

Vanda Pharmaceuticals Inc. (VNDA) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell VNDA stock right now?

Vanda Pharmaceuticals Inc. (VNDA) currently earns a Roarable Rating of D- (Sell — SELL) with 37/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

Q: What is VNDA's 12-month price target and RQD AI Jury consensus?

VNDA's 12-month base price target is $3.67 (range $2.86 to $10.44), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$4.05 +1.25% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Vanda Pharmaceuticals Inc. (VNDA) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $244.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VNDA)Realized 20D OHLCV Swing Band: ±11.7%

RSI-14 MOMENTUMOVERSOLD (<32)

26.730 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.20>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE5% OF RANGE

L: $4$4.05H: $10

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 3 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on VNDA

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (15)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (25)

Altman-Z 0.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (48)

16/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like VNDA

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VNDA)

✓Walkthrough of VNDA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VNDA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -42.96%▼ DESCENDING CHANNEL

2026-10-30O $4.03H $4.11L $3.74C $4.05VOL 1.79M

RES: $4.69SUP: $2.76SMA50: $4.79SMA200: $6.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VNDA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VNDA Butterfly Map → + Track VNDA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +8.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VNDA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VNDA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VNDA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VNDA)

Health Care Rank #751 of 1016 ⚔️ CAMP vs VNDA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VNDA vs. CAMP, LFCR, ELDN, EVMN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Vanda Pharmaceuticals Inc. (VNDA) ranks #751 by composite RQD confidence (37/100, grade D-) and #551 by equity capitalization ($244.9M). Within this direct 5-issuer industry benchmark cohort, VNDA leads on earnings valuation at N/A trailing P/E, while VNDA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LFCR currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with VNDA at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VNDA ACTIVE Vanda Pharmaceuticals Inc.	D-	37/100	—	—	-35.0%	+1.25%	$244.9M	Benchmark Subject
CAMP CAMP4 Therapeutics Corporation	E	34/100	—	—	-35.0%	+6.85%	$244.7M	/camp-vs-vnda →
LFCR Lifecore Biomedical Inc.	D	51/100	—	—	—	+0.15%	$246.8M	/lfcr-vs-vnda →
ELDN Eledon Pharmaceuticals Inc.	D	49/100	—	—	-35.0%	+10.15%	$247.0M	/eldn-vs-vnda →
EVMN Evommune Inc.	D-	43/100	—	—	-35.0%	+7.92%	$247.1M	/evmn-vs-vnda →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001347178

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vanda Pharmaceuticals Inc. (VNDA) reported GAAP revenue of $216.1M (+8.7% vs. FY2024 revenue of $198.8M , and +12.2% cumulative change since FY2023) , GAAP net income of -$220.5M, operating cash flow of -$109.4M, and free cash flow of -$110.4M (-579.8% YoY). On the balance sheet, VNDA closed FY2025 with $488.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$216.1M	-$220.5M	-$109.4M	-$110.4M	$488.9M	—
FY2024 (FY)	2024-12-31	$198.8M	-$18.9M	-$15.8M	-$16.2M	$656.2M	—
FY2023 (FY)	2023-12-31	$192.6M	$2.5M	$12.8M	$12.8M	—	—

3. VNDA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VNDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $4.05 (+1.25% 1D, market cap $244.9M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VNDA ranks #751 in composite RQD confidence.

How does VNDA compare to CAMP and LFCR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VNDA carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CAMP (CAMP4 Therapeutics Corporation) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $244.7M) and LFCR (Lifecore Biomedical Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $246.8M). Among the 5-stock peer group, VNDA leads on earnings multiple (N/A) while VNDA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VNDA?

Per VNDA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001347178), Vanda Pharmaceuticals Inc. generated $216.1M in revenue (+8.7% YoY), -$220.5M in net income, and -$110.4M in free cash flow against $488.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VNDA trading relative to its 50-day, 200-day, and 52-week technical levels?

VNDA last traded at $4.05 (+1.25% on volume of 2,704,250 shares), positioning the stock -15.45% below its 50-day simple moving average ($4.79) and -34.78% below its 200-day simple moving average ($6.21). Across its 52-week range of $3.74 to $9.94, VNDA sits at the 5.0% percentile with a 14-day RSI of 26.7 (OVERSOLD (<32)) and an implied next-earnings move of ±11.7% ($3.58 to $4.52).

VNDA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell VNDA stock right now?

Vanda Pharmaceuticals Inc. (VNDA) currently earns a Roarable Rating of D- (Sell — SELL) with 37/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is VNDA's 12-month price target and RQD AI Jury consensus?

VNDA's 12-month base price target is $3.67 (range $2.86 to $10.44), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: VNDA RQD Cockpit VNDA 12M Forecast VNDA Earnings & Move VNDA Dividends & DRIP VNDA Insiders & 13F VNDA Whale Options VNDA Profit Sankey VNDA News & Why